The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1493735
This article is part of the Research Topic Myeloid Cell Immunity and Tumor Immunotherapy View all articles
Myeloid response evaluated by noninvasive CT imaging predicts post-surgical survival and immune checkpoint therapy benefits in patients with hepatocellular carcinoma
Provisionally accepted- 1 Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
- 2 Zhuhai People's Hospital, Zhuhai, Guangdong Province, China
- 3 Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
- 4 School of Medicine and Bioinformatics Engineering, Northeastern University, Shenyang, Liaoning Province, China
- 5 First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China
- 6 Sun Yat-sen University, Guangzhou, Guangdong Province, China
The potential of preoperative CT in the assessment of myeloid immune response and its application in predicting prognosis and immune-checkpoint therapy outcomes in hepatocellular carcinoma (HCC) has not been explored.Methods: 165 patients with pathological slides and multi-phase CT images were included to develop a radiomics signature for predicting imaging-based myeloid response score (iMRS).Overall survival (OS) and recurrence-free survival (RFS) were assessed according to the iMRS risk group and validated in a surgical resection cohort (n = 98).The complementary advantage of iMRS incorporating significant clinicopathologic factors was investigated by the Cox proportional hazards analysis. Additionally, the iMRS in interring the benefits of immune checkpoint therapy was explored in an immunotherapy cohort (n = 36). We showed that AUCs of the optimal radiomics signature for iMRS were 0.941 (95% confidence interval [CI], 0.909-0.973) and 0.833 (0.798-0.868) in the training and test cohorts, respectively. High iMRS was associated with poor RFS and OS. The prognostic performance of the Clinical-iMRS nomogram was better than that of a single parameter (P < 0.05), with 1-, 3-, and 5-year C-index for RFS of 0.729, 0.709, and 0.713 in the training, test, and surgical resection cohorts, respectively. A high iMRS score predicted a higher proportion of objective response (vs progressive disease or stable disease; odds ratio, 2.311; 95% CI, 1.144-4.672; P = 0.020; AUC, 0.718) in patients treated with anti-PD-1 and PD-L1.Conclusions: iMRS may provide a promising method for predicting local myeloid immune responses in HCC patients, inferring postsurgical prognosis, and evaluating benefits of immune checkpoint therapy.
Keywords: Hepatocellular Carcinoma, Radiomics, Myeloid Cells, prognosis, Immunotherapy
Received: 09 Sep 2024; Accepted: 12 Nov 2024.
Copyright: © 2024 Peng, Zhang, Li, Wang, Sun, Zhao, Pan, Zhang, Wu, Yu, Wu, Weng, Lin, Liu, Zhan, Xu, Zheng, Zhang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kangqiang Peng, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
Wei Zhao, Zhuhai People's Hospital, Zhuhai, Guangdong Province, China
Jielin Pan, Zhuhai People's Hospital, Zhuhai, Guangdong Province, China
Xiao-Yang Zhang, School of Medicine and Bioinformatics Engineering, Northeastern University, Shenyang, 110167, Liaoning Province, China
Xiaoling Wu, First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong Province, China
Yulan Weng, Sun Yat-sen University, Guangzhou, 510275, Guangdong Province, China
Xiaowen Lin, Zhuhai People's Hospital, Zhuhai, Guangdong Province, China
Limin Zheng, Sun Yat-sen University, Guangzhou, 510275, Guangdong Province, China
Yaojun Zhang, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
Ligong Lu, Zhuhai People's Hospital, Zhuhai, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.